• Explore /
  • Poster
  • / Safety and efficacy of tazemetostat, an enhancer of zeste-homolog 2 inhibitor, in patients with relapsed or refractory malignant mesothelioma.

Safety and efficacy of tazemetostat, an enhancer of zeste-homolog 2 inhibitor, in patients with relapsed or refractory malignant mesothelioma.

Abstract Video & Slides Poster

Authors

Marjorie Zauderer

Marjorie Glass Zauderer

Memorial Sloan Kettering Cancer Center, New York, NY

Marjorie Glass Zauderer , Peter Wojciech Szlosarek , Sylvestre Le Moulec , Sanjay Popat , Paul Taylor , David Planchard , Arnaud Scherpereel , Thierry Marie Jahan , Marianna Koczywas , Martin Forster , Robert B. Cameron , Tobias Peikert , Evren Kocabas Argon , Neil Michaud , Jay Yang , Vikram Kansra , Dean A. Fennell

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Track

Lung Cancer

Sub Track

Mesothelioma

Clinical Trial Registration Number

NCT02860286

Citation

J Clin Oncol 38: 2020 (suppl; abstr 9058)

DOI

10.1200/JCO.2020.38.15_suppl.9058

Abstract #

9058

Poster Bd #

251

Abstract Disclosures

Similar Posters

First Author: Marjorie Glass Zauderer

First Author: Susan N. Chi

First Author: Connie Lee Batlevi

First Author: Erel Joffe